PMID- 33237495
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20220716
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Print)
IS  - 1776-2596 (Linking)
VI  - 15
IP  - 6
DP  - 2020 Dec
TI  - Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
PG  - 791-799
LID - 10.1007/s11523-020-00779-x [doi]
AB  - Oral darolutamide (Nubeqa) is a novel second-generation, nonsteroidal, selective 
      androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic 
      castration-resistant prostate cancer (nmCRPC). In the pivotal multinational, 
      phase 3 ARAMIS trial in men with nmCRPC, relative to placebo plus ongoing 
      androgen deprivation therapy (ADT), darolutamide (+ ADT) significantly prolonged 
      metastasis-free survival (MFS) at the time of the primary analysis and overall 
      survival (OS) at the time of the final OS analysis and was generally well 
      tolerated in extended follow-up. Albeit long-term data from the real-world 
      setting are required to fully define the safety profile of darolutamide, current 
      evidence from the final ARAMIS analysis indicates that darolutamide has a low 
      propensity for CNS-related adverse events (AEs) associated with other currently 
      approved second-generation AR inhibitors. Given the efficacy and safety evidence 
      from the final ARAMIS analysis and the key role of second-generation AR 
      inhibitors in the management of nmCRPC, darolutamide + ADT represents an 
      important emerging option for the treatment of men with nmCRPC who are at high 
      risk of developing metastatic prostate cancer.
FAU - Scott, Lesley J
AU  - Scott LJ
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Pyrazoles)
RN  - 0 (darolutamide)
SB  - IM
EIN - Target Oncol. 2022 May;17(3):381. PMID: 35511401
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Pyrazoles/pharmacology/*therapeutic use
PMC - PMC9072426
COIS- Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, 
      and declares no relevant conflicts of interest. All authors contributed to the 
      review and are responsible for the article content.
EDAT- 2020/11/26 06:00
MHDA- 2021/10/14 06:00
PMCR- 2020/11/25
CRDT- 2020/11/25 12:17
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/11/25 12:17 [entrez]
PHST- 2020/11/25 00:00 [pmc-release]
AID - 10.1007/s11523-020-00779-x [pii]
AID - 779 [pii]
AID - 10.1007/s11523-020-00779-x [doi]
PST - ppublish
SO  - Target Oncol. 2020 Dec;15(6):791-799. doi: 10.1007/s11523-020-00779-x.